Novo’s oral semaglutide edges out CagriSema, Lilly’s orforglipron as PCPs’ most-anticipated obesity med

"As both Novo Nordisk and Eli Lilly race to develop their long-anticipated oral GLP-1 obesity meds, a new report shows one taking a clear lead among potential prescribers.

Spherix Global Insights surveyed about 100 primary care physicians and endocrinologists about several of the oral obesity meds currently under development, including Novo’s oral semaglutide and CagriSema, as well as Lilly’s orforglipron.

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA decision in obesity, they did report high levels of familiarity with the med—since it’s been approved since 2019 for Type 2 diabetes and marketed in that indication as Rybelsus.Likely due to that familiarity, many of the doctors showed enthusiasm about oral semaglutide’s potential expansion into obesity, with around 90% of the group saying they expect to prescribe it within the first six months of its launch.

The PCPs, in particular, were most excited about oral semaglutide among the three upcoming oral obesity meds: More than 70% chose it as their most-preferred weight-loss agent in development. The endocrinologists surveyed, meanwhile, showed an almost equal three-way split among the meds, though CagriSema—which combines semaglutide with cagrilintide—nosed ahead with 36% of their votes.

“Given the strong pre-launch prescribing intentions, oral semaglutide is poised for swift market uptake upon FDA approval,” the Spherix analysts concluded, though they warned that “Novo Nordisk will need robust promotional efforts to counter currently low top-of-mind awareness and ensure prescribers are promptly informed of the approval once it occurs.”

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!